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Abstract 
BACKGROUND: Antibiotic resistance of microorganisms is the subject of numerous discussions and initiatives, it 
has a well-defined tendency to increase which is largely related to a big number of errors when prescribing 
antibacterial drugs at the outpatient stage of treatment and disease prevention, as well as a lack of information 
and data on the quantity and quality of antimicrobial therapy. One of the elements aimed at reducing antibiotic 
resistance growth is audit and analysis of application practice. 
AIM: To assess qualitative and quantitative characteristics for urinary tract infections treatment using antimicrobial 
drugs by general physicians at the outpatient level.  
MATERIALS AND METHODS: The Point Prevalence Survey (PPS) analysis of antimicrobial drugs prescription 
was conducted by general physicians of No. 1, 4, 5 Hospitals of Karaganda city. There was carried out a daily 
prospectively data collecting on antibacterial drugs prescription by Doctor of Medical institutions, which was 
performed during patients’ visit. For each person who was prescribed the AD, there was filled a special 
questionnaire developed by the European Center for Disease Prevention and Control, including passport data, 
data on disease and prescription of antibacterial drugs. There were considered 200 cases of antibiotic 
prescription. The study included patients of both sexes, all age groups, who were prescribed the antibiotic therapy 
for the UTI treatment. 
RESULTS: When selecting antimicrobial therapy, the Protocols for diagnosis and treatment indicate the need for 
a microbiological study to determine sensitivity to antibacterial drugs, that was not performed in 100% of cases, 
and initial treatment was empirically prescribed, namely, in 34% of cases there were used drugs from the 
cephalosporin group (Ceftriaxone), nitrofurans (Furazidin)-42%, fluoroquinolones (Levofloxacin)-24%. In treating 
acute cystitis, in most cases, alternative medications were prescribed, though according to current 
recommendations, first-line therapy includes fosfomycin trometamol, pivmecillins and nitrofurantoin macrocrystals, 
which according to the results of this study were not used at all. 
CONCLUSION: In most cases (71%), alternative antibacterial drugs were prescribed for initial treatment of urinary 
tract infections. In majority cases, the dosage regimen of antibacterial drugs, dosage frequency, treatment course 
did not meet current recommendations. 
 
 
 
 
Introduction 
 
The number of urinary system diseases in the 
Republic of Kazakhstan tends to continuous growth, 
mainly due to urinary tract infections (UTI). So, in 
2015, the overall incidence in this nosological 
category was 7532.2, in 2016-8784.8, in 2017 - 
8765.7 per 100,000 people. In absolute numbers, the 
statistics is the following: 2015-1321460 persons, 
2016-1563158 persons, 2017-1581114 persons [1], 
[2]. 
Every year in the US, more than 7 million 
people with the UTI symptoms are seeking 
specialised medical assistance, and about 15% of all 
prescribed antibacterial drugs (AD) are used 
specifically by a group of childbearing age female 
patients. A similar trend is observed in Western 
European countries. Among childbearing age women, 
the UTI is diagnosed ten times more often than in 
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men. Nearly half of women in this age group have had 
the UTI during their life with every third woman under 
the age of 24, and from 20 years old before 
menopause women’s cystitis is diagnosed 50 times 
more often than in men, which indicates the need to 
improve the diagnosis and treatment of the UTI in 
women, which is also important in periconceptional 
supplementation due to strong correlation with 
infectious diseases of the pelvic organs, especially 
when the infection is generalized [3]. Besides, savings 
by reducing antibiotics costs may be greater than the 
cost of intervention or program (from $ 200,000 to $ 
900,000, depending on the study) [4], [5]. 
According to numerous studies, the etiological 
factor in approximately 70 – 85% of cases are 
Enterobacteriaceae. The remaining pathogens 
(Staphylococcus saprophyticus, Pseudomonas 
aeruginosa, Enterococcus faecalis) are much less 
common [6], [7], [8]. Today, the literature suggests the 
choice of therapy drugs for urinary tract infections are 
cephalosporins of the II-III generations, 
fluoroquinolones and aminoglycosides, which 
indicates an increase in resistance [3]. 
Antibiotic resistance of microorganisms is the 
subject of numerous discussions and initiatives [9], it 
has a well-defined tendency to increase which is 
largely related to a big number of errors when 
prescribing antibacterial drugs at the outpatient stage 
of treatment and disease prevention, as well as a lack 
of information and data on the quantity and quality of 
antimicrobial therapy. One of the elements aimed at 
reducing antibiotic resistance growth is audit and 
analysis of application practice. 
The Point Prevalence Survey (PPS) is the 
most appropriate tool for monitoring doctors’ actions 
regarding antibiotics. The PPS is pointed prevalence 
study which allows identifying the goals of doctors in 
charge of diseases therapy. At the same time, the 
points prevalence means the number of people with a 
certain characteristic in a selected period of the 
relatively interested population for researchers. The 
Global Prevalence Study (Global PPS) on 
consumption and antimicrobial resistance was 
developed after the Fourth Worldwide Forum on 
Infections and Antimicrobial Resistance. Its goal was 
to assess the international prevalence of antimicrobial 
use and resistance with a focus on countries with low 
resources, support and experience [10]. The project 
was based on the results of three-pointed prevalence 
studies conducted by the European antimicrobial 
consumption supervision in 2006 and 2009 [11], [12]. 
Many modern studies have brought into sharp 
focus that the PPS analysis is a valid method of 
rationality assessment for antimicrobial therapy 
prescribing in each medical institution [13], [14], [15], 
[16], [17]. Several studies [18], [19], [20], [21] on 
applicability and benefits of the antimicrobial use 
prevalence points survey have shown its value within 
the range of European hospitals. In addition, the 
European supervision of antimicrobial consumption 
network methods have been adapted for the 
European Center for Disease Prevention for the use 
of antimicrobial agents in emergency hospitals [22] 
and determination the antibiotic resistance in the 
European children’s project which focuses on 
antimicrobial drugs for children and newborns 
worldwide [23], [24], [25]. Thus, to prevent resistance 
growth, it is necessary to conduct an analysis for 
rational antibiotics uses based on valid methods. 
Purpose of the study: to assess qualitative 
and quantitative characteristics for urinary tract 
infections treatment using antimicrobial drugs by 
general physicians at the outpatient level.  
 
 
Material and Methods 
 
The Point Prevalence Survey (PPS) analysis 
of antimicrobial drugs prescription was conducted by 
general physicians of No. 1, 4, 5 Hospitals of 
Karaganda city. There was carried out a daily 
prospectively data collecting on antibacterial drugs 
prescription by Doctor of Medical institutions, which 
was performed during patients’ visit. For each person 
who was prescribed the AD, there was filled a special 
questionnaire developed by the European Center for 
Disease Prevention and Control [26], including 
passport data, data on disease and prescription of 
antibacterial drugs. There were considered 200 cases 
of antibiotic prescription. The study included patients 
of both sexes, all age groups, who were prescribed 
the antibiotic therapy for the UTI treatment. 
 
 
Results 
 
In the research, 200 cases of the AD 
prescription for urinary tract infections therapy were 
considered. The survey included 161(80.5%) women 
and 39 (19.5%) men.  
 
Figure 1: Sex-age structure of those under study by groups 
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One hundred twenty-one persons under study 
(75%) are related to the childbearing age women 
category. Their sex-age structure by groups is 
provided in Figure 1. 
As the Figure indicates, women are 4 times 
more than men which corresponds to literary data [3]. 
When analysing the obtained data, there was 
data homogeneity: most often antibacterial drugs were 
prescribed by general physicians in the Hospitals No. 
1, it is 46% of cases, in the Hospitals No. 4 and No. 5 
it is 31% and 23% respectively. The structure of the 
nosology is shown in Figure 2. 
 
Figure 2: Urinary tract infections structure 
 
The most common reason for antibiotics 
prescription was a chronic pyelonephritis 
exacerbation; it is 48%. 
Figure 3 shows the UTI disease incidence in 
men of different age groups. As can be seen, in most 
cases, urethritis occurs in 40 – 60 years old men, 
which corresponds to modern data [27]. 
 
Figure 3: The incidence of UTIs in different age groups 
 
In women of all age groups, the chronic 
pyelonephritis exacerbation is most common, which 
corresponds to the literature data (Figure 3) [3]. 
When selecting antimicrobial therapy, the 
Protocols for diagnosis and treatment indicate the 
need for a microbiological study to determine 
sensitivity to antibacterial drugs, that was not 
performed in 100% of cases, and initial treatment was 
empirically prescribed, namely, in 34% of cases there 
were used drugs from the cephalosporin group 
(Ceftriaxone), nitrofurans (Furazidin)-42%, 
fluoroquinolones (Levofloxacin)-24%. 
Figure 4 shows the prescription of different 
antibiotics for urinary tract infections treatment. 
 
Figure 4: Prescription frequency of different antibiotics for urinary 
tract infections treatment 
 
In case of chronic pyelonephritis 
exacerbation, in most cases (71%) (Figure 4) there 
were used nitrofurans 100 mg, 4 times a day, the 
treatment was 7-10 days, although according to the 
literature they are not the first-choice drugs (Table 1) 
[3]. 
Table 1: Dosing Schedule, frequency and treatment course of 
different antibiotics  
Drug Dosage, mg 
(day) 
Number of 
cases 
Dosage 
frequency 
Administration 
route 
Treatment 
course, days 
Levofloxacin 500 48 1 orally none 
Ceftriaxone 1000 60 2 parenterally 7 
2000 8 1 parenterally none 
Furazidin 100 68 4 orally 10 
100 16 4 orally 7 
 
Cephalosporins (Cefriaxone) were prescribed 
only in 17% of cases (Figure 4), the drug dosage 
varied from 1000-2000 mg 1-2 times a day, the course 
lasted for 7 days, although according to literature 
data, the 2-3 class cephalosporins are alternative-
choice drugs: Cefpodoximum axetil-250 mg each 2 
times a day; Cefpodoximum-100 mg 2 times a day; 
ceftibutenum or cefiximum-400 mg per day; -protected 
aminopenicillins: amoxicillin/clavulanic acid 500 
mg/125 mg 3 times a day [3]. 
 
 
Discussion 
 
Moreover, according to the WHO 
recommendations, on the outpatient stage, it is 
preferable to use drugs with a non-invasive 
administration route since parenteral forms reduce the 
level of compliance between doctor and patient and 
reduce treatment compliance in the latter [28]. This 
situation provokes the development of complications, 
process chronization and antibiotic resistance growth 
of pathogens. Also, the parenteral forms are 
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prescribed when it is impossible to take medications 
orally (nausea, vomiting), the so-called “switch” 
therapy: the initial parenteral administration of a drug 
with further change oral administration after 
improvement. 
Fluoroquinolones (Levofloxacin) were 
prescribed in 12% of cases (Figure 4) with a dosage 
of 500 mg a day which corresponds to the literature 
data, but the therapy course duration is not indicated. 
Although the selected drugs for community-acquired 
uncomplicated pyelonephritis from the perspective of 
evidentiary medicine are fluoroquinolones: 
ciprofloxacin – 500 mg, 2 times a day; Levofloxacin – 
500 mg, once a day; Norfloxacin – 400 mg, 2 times a 
day; Ofloxacin – 200-400 mg, 2 times a day during 10-
14 days (1b level of evidence, recommendation grade 
B) [3]. 
In the majority of cases, the multiplicity of 
furazidine intake does not meet the recommendations 
based on drug pharmacodynamics [29], which 
indicates poor knowledge of the drug 
pharmacodynamics. 
In treating acute cystitis, in most cases, 
alternative medications were prescribed, though 
according to current recommendations, first-line 
therapy includes fosfomycin trometamol, pivmecillins 
and nitrofurantoin macrocrystals, which according to 
the results of this study were not used at all. Co-
trimoxazole is the dosage 160 / 800 mg, 2 times a day 
for 3 days or trimethoprim (TMP) 200 mg, 2 times a 
day for 5 days can be used as the first-line therapy in 
areas, where E. coli resistance < 20 % [3]. In 39% of 
cases, there were prescribed cephalosporins 
(ceftriaxone), fluoroquinolones (levofloxacin) - 34% 
and nitrofurans (furazidin)-27% (Figure 4). Alternative 
antibiotics are ciprofloxacin-250 mg, 2 times a day, 
ciprofloxacin with a prolonged action at the dose of 
500 mg, 1 time a day, levofloxacin at the dose of 250 
mg, 1 time a day, norfloxacin-400 mg, 2 times a day, 
each of the drugs taken a three-day course [3]. 
The same situation was observed when 
prescribing antibiotics for urethritis, preference was 
given to the second-line drugs, so fluoroquinolones 
(levofloxacin) were administered in 51% of cases, and 
the first-line drugs, namely cephalosporins, were 
prescribed only in 16% of cases (Figure 4). Moreover, 
the dosage regimen of antibacterial drugs, dosage 
frequency, treatment course did not meet current 
recommendations [3]. 
Documentation analysis has shown that the 
age-specific features of patients were not taken into 
account when prescribing antibiotics and selecting a 
dose, and in no case, the glomerular filtration rate was 
measured [29]. 
In conclusion, in most cases (71%), 
alternative antibacterial drugs were prescribed for 
initial treatment of urinary tract infections. In majority 
cases, the dosage regimen of antibacterial drugs, 
dosage frequency, treatment course did not meet 
current recommendations. Also, there were prescribed 
antibiotics with the parenteral administration route, 
although, according to the WHO recommendations, it 
is preferable to use drugs with a non-invasive 
administration route in the outpatient stage. 
The results obtained from this PPS study, 
which was first conducted in municipal hospitals, 
reveal several specific opportunities for improving the 
practice of antibacterial drugs use, which may lead to 
improved treatment results of patient, resistance 
growth prevention and reduced health care costs. 
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